Remove Hospitals Remove Immune Response Remove Therapies
article thumbnail

POLB 001: tackling cytokine storms before they start

Drug Target Review

In the ever-evolving landscape of immuno-oncology, managing the side effects of advanced therapies has become just as important as enhancing their efficacy. Existing therapies, such as tocilizumab, work by blocking specific inflammatory pathways but often come with limitations.

article thumbnail

Innovating in Autoimmune and Bone Health Research: Driving Progress for Better Patient Outcomes

Conversations in Drug Development Trends

Given the complexity and widespread impact of autoimmune and bone health conditions, developing new therapies is essential. For instance, drugs like belimumab, a monoclonal antibody, have shown promise in treating systemic lupus erythematosus and lupus nephritis by reducing the overactive immune response.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Why brain cancer is often resistant to immunotherapy

Broad Institute

This study provides us with the data we need to create myeloid-targeting strategies to modulate these programs and make immunotherapies more effective for brain tumor patients, said Tyler Miller, co-first author on the study and a resident in clinical pathology at Massachusetts General Hospital when the study began.

article thumbnail

Scientists discover network of cells and genes involved in Crohn’s disease complication

Broad Institute

To better understand the biological processes at play in strictures, Broad Institute and Massachusetts General Hospital researchers analyzed individual cells from the intestinal tissue of Crohn’s disease patients, measuring gene activity and mapping the cells’ location in the tissue.

Disease 111
article thumbnail

FDA takes major step to ease access to CAR-T therapy

BioPharma Drive: Drug Pricing

Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. You can unsubscribe at anytime.

Therapies 178
article thumbnail

Innovation in Autoimmune and Bone Health Research: Driving Progress for Better Patient Outcomes

Conversations in Drug Development Trends

Given the complexity and widespread impact of autoimmune and bone health conditions, developing new therapies is essential. For instance, drugs like belimumab, a monoclonal antibody, have shown promise in treating systemic lupus erythematosus and lupus nephritis by reducing the overactive immune response.

article thumbnail

The Ongoing Challenges of Understanding Long COVID and Exploring Innovative Solutions

Perficient: Drug Development

This pattern may relate to differences in immune response, organ-specific vulnerability, or patterns of healthcare utilization. Differential Immune Response: Women with Long COVID typically show higher levels of IL-6 compared to men, particularly those with central sensitization phenotypes.